These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19157062)

  • 41. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis.
    Iida K; Itoh K; Maher JM; Kumagai Y; Oyasu R; Mori Y; Shimazui T; Akaza H; Yamamoto M
    Carcinogenesis; 2007 Nov; 28(11):2398-403. PubMed ID: 17602169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
    Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ
    PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 and its downstream proteins as molecular targets of cancer.
    Sun Y
    Mol Carcinog; 2006 Jun; 45(6):409-15. PubMed ID: 16652354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
    Wang J; Ouyang W; Li J; Wei L; Ma Q; Zhang Z; Tong Q; He J; Huang C
    Cancer Res; 2005 Aug; 65(15):6601-11. PubMed ID: 16061640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of the tumor suppressor p53 pathway in the cellular DNA damage response to zinc oxide nanoparticles.
    Ng KW; Khoo SP; Heng BC; Setyawati MI; Tan EC; Zhao X; Xiong S; Fang W; Leong DT; Loo JS
    Biomaterials; 2011 Nov; 32(32):8218-25. PubMed ID: 21807406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer.
    Hussain SP; Harris CC
    Mutat Res; 1999 Jul; 428(1-2):23-32. PubMed ID: 10517975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
    Nakanishi A; Kitagishi Y; Ogura Y; Matsuda S
    Int J Oncol; 2014 Jun; 44(6):1813-9. PubMed ID: 24718924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex.
    Carrà G; Crivellaro S; Taulli R; Guerrasio A; Saglio G; Morotti A
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916821
    [No Abstract]   [Full Text] [Related]  

  • 49. Exploiting the p53 pathway for cancer diagnosis and therapy.
    Woods YL; Lane DP
    Hematol J; 2003; 4(4):233-47. PubMed ID: 12872148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
    Go C; Li P; Wang XJ
    Cancer Res; 1999 Jun; 59(12):2861-8. PubMed ID: 10383147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Post-translational modification of p53 in tumorigenesis.
    Bode AM; Dong Z
    Nat Rev Cancer; 2004 Oct; 4(10):793-805. PubMed ID: 15510160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A molecular mechanism of nickel (II): reduction of nucleotide excision repair activity by structural and functional disruption of p53.
    Kim YJ; Lee YJ; Kim HJ; Kim HS; Kang MS; Lee SK; Park MK; Murata K; Kim HL; Seo YR
    Carcinogenesis; 2018 Sep; 39(9):1157-1164. PubMed ID: 29931256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Signalling to p53: where does it all start?
    Kastan MB
    Bioessays; 1996 Aug; 18(8):617-9. PubMed ID: 8760334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Of flies and men; p53, a tumour suppressor.
    Sutcliffe JE; Brehm A
    FEBS Lett; 2004 Jun; 567(1):86-91. PubMed ID: 15165898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p53 modulation of the DNA damage response.
    Helton ES; Chen X
    J Cell Biochem; 2007 Mar; 100(4):883-96. PubMed ID: 17031865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene expression profiling of p53(+/-) knockout and wild-type mice following diethylstilbestrol administration.
    Salleh MN; Ismail P; Abdullah AS; Taufiq-Yap YH
    IUBMB Life; 2004 Jul; 56(7):409-16. PubMed ID: 15545218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-Canonical Cell Death Induced by p53.
    Ranjan A; Iwakuma T
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Possible involvement of O6-methylguanine formation and p53 dysfunction in mouse urinary bladder carcinogenesis.
    Fukushima S
    Mutat Res; 2001 Jun; 477(1-2):125-30. PubMed ID: 11376694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. VHL and p53: tumor suppressors team up to prevent cancer.
    Semenza GL
    Mol Cell; 2006 May; 22(4):437-9. PubMed ID: 16713574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [corrected] induces CRM1-dependent p53 nuclear accumulation in human bronchial epithelial cells.
    Chen L; Shao C; Cobos E; Wang JS; Gao W
    Toxicol Sci; 2010 Jul; 116(1):206-15. PubMed ID: 20421341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.